

**David K. Wilcox, Ph.D.**  
Vice President  
Product Safety, Regulatory, and Information  
Global Technology  
Telephone (732) 878-7350  
Telefax (732) 878-7135  
Internet: david\_wilcox@colpal.com

October 4, 2004

Dockets Management Branch (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane, Room 1061  
Rockville, MD 20852


**RE: Docket No. 81N-033P – Oral Health Care Drug Products for Over-the-Counter Human Use; Antigingivitis/Antiplaque Drug Products; Notice of Eligibility; Request for Data and Information on Triclosan (69 Fed. Reg. No. 128, Page 40640 - 40641, July 6, 2004)**

These comments are submitted on behalf of the Colgate-Palmolive Company (Colgate-Palmolive) in response to the captioned Request for Data and Information.

For the reasons set forth in our comments, Colgate-Palmolive believes that, while Triclosan in an oral care product has been proven safe and effective for use in a specific formulation approved under FDA's New Drug Approval system, there exists inadequate data supporting a general recognition of the efficacy of triclosan alone for antiplaque and antigingivitis indications.

We confirm FDA's agreement that the second half of Colgate-Palmolive's comments will be submitted before or during the next open comment period which has been requested of and agreed to by the Agency, and that the second portion of our comments will also be part of the record in this proceeding.

Respectfully submitted,



David K. Wilcox, Ph.D.  
Vice President  
Product Safety, Regulatory, and Information  
Global Technology

**81N-033P**

**C 26**